AC Immune SA

Equities

ACIU

CH0329023102

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-14 EDT 5-day change 1st Jan Change
4.26 USD -9.94% Intraday chart for AC Immune SA -10.69% -14.80%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
BTIG Starts AC Immune With Buy Rating, $8 Price Target MT
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care MT
Top Midday Gainers MT
AC Immune Enters Licensing Deal for Alzheimer's Disease Drug Candidate MT
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Key Inflation Reports MT
Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday MT
Top Premarket Gainers MT
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate MT
AC Immunity Shares Soar on Exclusive License Deal with Takeda DJ
AC Immune SA Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer?s Disease CI
AC Immune Files $350 Million Mixed Shelf MT
AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Certain Common Shares of AC Immune SA are subject to a Lock-Up Agreement Ending on 14-FEB-2024. CI
AC Immune to Regain Global Rights of Crenezumab, Semorinema MT
Roche terminates licensing agreement with AC Immune CF
AC Immune SA Announces Termination of the Research Collaboration and License Agreement with Genentech, Inc CI
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson's Diseases CI
AC Immune SA(NasdaqGM:ACIU) added to NASDAQ Biotechnology Index CI
Sector Update: Health Care Stocks Retreating Late Afternoon MT
Sector Update: Health Care Stocks Softer in Afternoon Trading MT
AC Immune SA Announces its Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial CI
AC Immune to Launch Mid-Stage Trial of Alzheimer's Disease Therapy; Prices $50.1 Million Common Stock Offering; Shares Rise MT
Chart AC Immune SA
More charts
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.797 CHF
Average target price
9.283 CHF
Spread / Average Target
+144.50%
Consensus
  1. Stock Market
  2. Equities
  3. ACIU Stock
  4. News AC Immune SA
  5. AC Immune Enters Licensing Deal for Alzheimer's Disease Drug Candidate